Success Metrics

Active Trials
4(80%)

Phase Distribution

Ph phase_2
1
20%
Ph not_applicable
3
60%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Other(1)

Detailed Status

Recruiting3
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (25.0%)
N/A3 (75.0%)

Trials by Status

active_not_recruiting120%
recruiting360%
unknown120%

Recent Activity

4 active trials
Showing 5 of 5
active_not_recruiting

Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study

NCT07608419
recruitingnot_applicable

68Ga-PSMA PET in the Renal Cell Carcinoma

NCT04987086
recruitingphase_2

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

NCT03495427
recruitingnot_applicable

The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)

NCT06867588
unknownnot_applicable

68Ga-PSMA PET in the Prostate Cancer

NCT04967001

Clinical Trials (5)

Showing 5 of 5 trials
NCT07608419

Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study

Active Not Recruiting
NCT04987086Not Applicable

68Ga-PSMA PET in the Renal Cell Carcinoma

Recruiting
NCT03495427Phase 2

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Recruiting
NCT06867588Not Applicable

The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)

Recruiting
NCT04967001Not Applicable

68Ga-PSMA PET in the Prostate Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
5